Citeline (PRIVATE.CITELINE)

Overall impact
C (50)

Commentary

Citeline is an average overall performer. With a 'C' rating of 50.3 for overall impact (42nd percentile compared to all companies), Citeline ranks 70th out of 76 industry peers, behind IMAC, Enzo Biochem, Invitae and 66 others, and ahead of Bio-Rad Laboratories, Lonza, Natera and 3 others. On top material causes for Citeline's industry (Healthcare Software & Services), Citeline performs well in Disease Eradication (91.2 score) and Child and Maternal Health (89.8) and performs poorly in Technology Innovation (30.4 score), Free, Secure Flow of Information (13.2), Accountable Institutions (34.4) and 4 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.CITELINE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2021
Employees
500
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
PRIVATE.CITELINE
Description
Provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance catering to global pharma and life sciences analytics markets. The company offers insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for clinical trials across the world. This thereby enables pharmaceutical companies and CROs in their clinical trial design, commercial strategy and regulatory compliance processes to maximize the likelihood of success of introducing products to market.
Material causes
Ethos considers the following causes material for Citeline, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.